2025
Functional connectome-based predictive modeling of suicidal ideation
Averill L, Tamman A, Fouda S, Averill C, Nemati S, Ragnhildstveit A, Gosnell S, Akiki T, Salas R, Abdallah C. Functional connectome-based predictive modeling of suicidal ideation. Journal Of Affective Disorders 2025, 387: 119518. PMID: 40441623, DOI: 10.1016/j.jad.2025.119518.Peer-Reviewed Original ResearchConceptsSuicidal ideationAssociated with increased suicidal ideationRecurrent major depressive disorderConnectome-based predictive modelingResting-state functional magnetic resonance imagingMechanisms of suicidal behaviorAssociated with suicidal ideationFunctional magnetic resonance imagingMajor depressive disorderDorsal salience networkIncreased suicidal ideationIncreased network integrationIncreased suicide riskThe Menninger ClinicNetwork integrationReduced network integrationRelative to controlsCentral executiveDepressive disorderDepressive episodeSalience networkNeural alterationsSuicidal behaviorSuicide riskBrain networksA multicenter cross-sectional study of gambling disorder among patients with methamphetamine use disorder in drug rehabilitation centers: prevalence, correlates, and network analysis
Peng P, Hao Y, Zhang X, Ma Y, Liu X, Shen D, Shen W, Zhao B, Li D, Beck S, Nunez Y, Potenza M, Gelernter J, Liu T, Yang B. A multicenter cross-sectional study of gambling disorder among patients with methamphetamine use disorder in drug rehabilitation centers: prevalence, correlates, and network analysis. Annals Of General Psychiatry 2025, 24: 12. PMID: 40033412, PMCID: PMC11877697, DOI: 10.1186/s12991-025-00546-0.Peer-Reviewed Original ResearchSemi-Structured Assessment for Drug Dependence and AlcoholismDSM-5 diagnostic criteriaGambling disorderDSM-5Antisocial personality disorderMethamphetamine use disorderSubstance use disordersDiagnostic criteriaPersonality disorderBridge symptomsDepressive episodeDrug rehabilitation centersCentral symptomsPsychiatric diagnosisGambling durationUse disorderSelf-harmChildhood experiencesMethamphetamineAlcohol useViolent experiencesDisordersManifest symptomsChinese versionMDELUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES
Bhagwagar *, Kozauer S, Earley W, Huo J, Sachs G, Durgam S. LUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES. The International Journal Of Neuropsychopharmacology 2025, 28: i316-i316. PMCID: PMC11814723, DOI: 10.1093/ijnp/pyae059.563.Peer-Reviewed Original ResearchClinical Global Impression Scale-SeverityMajor depressive disorderMADRS total scoreClinical Global Impression Scale-Severity scoresAnxious distressBipolar depressionBipolar II disorderDSM-5Bipolar disorderTotal scoreII disorderBipolar IDepressive disorderDepressive episodeAssociated with major depressive disorderDepression Rating ScaleDSM-5 criteriaBipolar disorder diagnosisPost-hoc analysis of studyIncreased suicide riskPoor treatment responseSingle-item scoresEpisode specifierTreat schizophreniaDisorder diagnosisLUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER
Bhagwagar *, Kozauer S, Earley W, Chen C, Huo J, Stahl S, McIntyre R, Durgam S. LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER. The International Journal Of Neuropsychopharmacology 2025, 28: i19-i19. PMCID: PMC11815047, DOI: 10.1093/ijnp/pyae059.033.Peer-Reviewed Original ResearchBipolar depressionBipolar II disorderII disorderLumateperone treatmentMDD populationBipolar IDSM-5Baseline to dayDSM-5-TRIncreased suicide riskMixing featuresPoor treatment responseAdverse eventsMADRS totalTreatment-emergent adverse eventsCGI-S scoresHypomanic symptomsDepressive disorderExtrapyramidal symptomsTreat schizophreniaDepressive episodeConsistent with prior studiesLumateperoneSuicide riskMDDStructural Brain Changes Associated With Risky Drinking in Late-Life Depression
Steffens D, Wang L, Manning K, Pearlson G. Structural Brain Changes Associated With Risky Drinking in Late-Life Depression. The American Journal Of Geriatric Psychiatry Open Science Education And Practice 2025, 6: 1-14. PMID: 40535612, PMCID: PMC12176382, DOI: 10.1016/j.osep.2025.01.003.Peer-Reviewed Original ResearchStructural brain changesBrain changesAlcohol useAlcohol consumptionCortical thicknessFronto-striatal circuitsInferior parietal sulcusVolumetric brain changesFrontal cortical regionsLate-life depressionDecreased depression severityModerate drinkersDecreased alcohol consumptionOlder adultsRisky drinkersRisky alcohol useImpact of alcohol useCognitive batteryDepression severityDepressive episodeDSM criteriaStudy psychiatristClinical interviewOlder depressivesPosterior cingulate
2024
Cognitive Remediation in Patients With Bipolar Disorder: A Randomized Trial by Sequential tDCS and Navigated rTMS Targeting the Primary Visual Cortex
Zhou H, Wang M, Xu T, Zhang X, Zhao X, Tang L, Zhao P, Wang D, Lai J, Wang F, Zhang S, Hu S. Cognitive Remediation in Patients With Bipolar Disorder: A Randomized Trial by Sequential tDCS and Navigated rTMS Targeting the Primary Visual Cortex. CNS Neuroscience & Therapeutics 2024, 30: e70179. PMID: 39703101, PMCID: PMC11659637, DOI: 10.1111/cns.70179.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationNeuronavigated repetitive transcranial magnetic stimulationTranscranial direct current stimulationBipolar disorderNavigated repetitive transcranial magnetic stimulationNon-invasive brain stimulationDepressive symptomsBD patientsRating ScaleYoung Mania Rating ScaleHamilton Depression Rating ScaleCognitive impairmentTHINC-integrated toolMania Rating ScaleDepression Rating ScaleTranscranial direct current stimulation treatmentImprove cognitive impairmentVisual cortexTHINC-itCognitive remediationDepressive episodeTranscranial magnetic stimulationNeurocognitive effectsNeurocognitive functionDirect current stimulationDelays in bipolar depression treatment in primary care vs. integrated behavioral health and specialty care
Park J, Breitinger S, Savitz S, Gardea-Resendez M, Singh B, Williams M, Frye M. Delays in bipolar depression treatment in primary care vs. integrated behavioral health and specialty care. Journal Of Affective Disorders 2024, 369: 404-410. PMID: 39389118, DOI: 10.1016/j.jad.2024.10.011.Peer-Reviewed Original ResearchIntegrated behavioral healthBipolar depression treatmentBipolar depressionBipolar disorderCollaborative care modelPrimary careCare modelSpecialty clinicsDepression treatmentEpisodes of bipolar depressionBehavioral healthDSM-5 criteriaSwitching to monotherapyPharmacological treatment patternsRetrospective study of adultsDepressive episodeDSM-5Mood stabilizersCompare treatment recommendationsStudy of adultsAntidepressant useGroup differencesDepression careEvidence of delayRetrospective study designNeocortical serotonin 2A receptor binding, neuroticism and risk of developing depression in healthy individuals
Sankar A, Ziersen S, Ozenne B, Dam V, Beaman E, Kessing L, Fisher P, Budtz-Jørgensen E, Knudsen G, Miskowiak K, Frokjaer V. Neocortical serotonin 2A receptor binding, neuroticism and risk of developing depression in healthy individuals. Nature Mental Health 2024, 2: 1231-1238. DOI: 10.1038/s44220-024-00299-x.Peer-Reviewed Original ResearchRisk of depressionFacets of neuroticismPersonality trait neuroticismPathophysiology of depressionSerotonin 2A receptorMolecular brain imagingHigh neuroticismTrait neuroticismDepressive episodeNeuroticismDepression diagnosisHealthy individualsDepressionReceptor bindingBrain imagingDanish registersCause-specific Cox regression analysesEvaluation of clinical strategiesIndividualsCox regression analysisPsychotherapyClinical strategiesPsychedelicsSerotoninRegression analysisKetamine vs Electroconvulsive Therapy for Treatment-Resistant Depression
Jha M, Wilkinson S, Krishnan K, Collins K, Sanacora G, Murrough J, Goes F, Altinay M, Aloysi A, Asghar-Ali A, Barnett B, Chang L, Costi S, Malone D, Nikayin S, Nissen S, Ostroff R, Reti I, Wolski K, Wang D, Hu B, Mathew S, Anand A. Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression. JAMA Network Open 2024, 7: e2417786. PMID: 38916891, PMCID: PMC11200139, DOI: 10.1001/jamanetworkopen.2024.17786.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionQIDS-SR16 scoresElectroconvulsive therapy groupElectroconvulsive therapyQIDS-SR16Measure of premorbid intelligencePosttraumatic stress disorder diagnosisTrial of electroconvulsive therapyNonpsychotic depressive episodeImpaired memory recallAssociated with differential improvementStress disorder diagnosisIntravenous ketamineEnd-of-treatment visitInfusion of ketamineMADRS scorePremorbid intelligenceResistant depressionDepressive episodeMeasures mixed-effects modelsFalse discovery rate adjustmentDisorder diagnosisMemory recallSevere depressionDifferential improvementNational trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States
Rhee T, Bommersbach T, Rosenheck R, Nierenberg A, McIntyre R. National trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States. Journal Of Affective Disorders 2024, 358: 342-349. PMID: 38734245, DOI: 10.1016/j.jad.2024.05.044.Peer-Reviewed Original ResearchTreatment-resistant depressionMajor depressive episodeSuicidal ideationDepressive episodeAverage annual percent changePast-year suicide attemptPast-year suicidal ideationPast-year major depressive episodePrevalence of suicidal ideationSuicide prevention effortsNational Survey of Drug Use and HealthUS adultsSuicide attemptsDrug Use and HealthNon-pharmacological interventionsHigh-risk populationIdeationAnnual percent changeTreatment resistanceNo significant differenceDiagnostic criteriaPreventive servicesAdultsPercent changeSignificant differenceSerum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders
Li Y, Wang L, Huang J, Zhang P, Zhou Y, Tong J, Chen W, Gou M, Tian B, Li W, Luo X, Tian L, Hong L, Li C, Tan Y. Serum neuroactive metabolites of the tryptophan pathway in patients with acute phase of affective disorders. Frontiers In Psychiatry 2024, 15: 1357293. PMID: 38680780, PMCID: PMC11046465, DOI: 10.3389/fpsyt.2024.1357293.Peer-Reviewed Original ResearchYoung Mania Rating ScaleBD-DAffective disordersBD-MDepressive symptomsHamilton Depression Scale-17 itemsRemission of depressive symptomsKynurenic acidMania Rating ScaleAcute manic episodeWeeks of antidepressantsRisk of MDDKynurenine pathwayAssociated with remissionAntipsychotic medicationDisrupt tryptophan metabolismManic symptomsDepressive disorderBD-D.Depressive episodeHAMD-17Mood stabilizersManic episodesBipolar disorderTryptophan pathwayExploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2024, 34: 73-79. PMID: 38170185, PMCID: PMC11262580, DOI: 10.1089/cap.2023.0047.Peer-Reviewed Original ResearchDepression symptom improvementTreatment-resistant depressionChildren's Depression Rating ScaleReuptake inhibitor medicationsDepression Rating ScaleSymptom improvementAntidepressant responseInhibitor medicationKetamine responseAdolescent treatment-resistant depressionRapid-acting antidepressant agentsSelective serotonin reuptake inhibitor medicationsSerotonin reuptake inhibitor medicationsKetamine’s antidepressant responseCurrent depressive episodeSevere depressive symptomsGreater symptom improvementAttention-deficit/hyperactivity disorder diagnosisFuture therapeutic useAntidepressant medicationMedication trialsCrossover trialAntidepressant agentsClinical variablesDepressive episode
2023
Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis
Rhee T, Shim S, Popp J, Trikalinos T, Rosenheck R, Kellner C, Seiner S, Espinoza R, Forester B, McIntyre R. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Molecular Psychiatry 2023, 29: 750-759. PMID: 38123725, DOI: 10.1038/s41380-023-02366-8.Peer-Reviewed Original ResearchMajor depressive episodeStandardized mean differenceElectroconvulsive therapyAnesthetic agentsDepressive symptomsDepressive episodeRelative riskDiagnosis of MDESystematic reviewKetamine-treated patientsSafety of ketamineSerious adverse eventsResultsTwenty-two studiesMethodsPubMed/MEDLINEImportant clinical considerationsRandom-effects modelCognitive performanceAdverse eventsAntidepressant efficacyECT useTrials RegistryClinical efficacyCochrane LibraryWorse outcomesPatient profilesLongitudinal resting-state network connectivity changes in electroconvulsive therapy patients compared to healthy controls
Verdijk J, van de Mortel L, Doesschate F, Pottkämper J, Stuiver S, Bruin W, Abbott C, Argyelan M, Ousdal O, Bartsch H, Narr K, Tendolkar I, Calhoun V, Lukemire J, Guo Y, Oltedal L, van Wingen G, van Waarde J. Longitudinal resting-state network connectivity changes in electroconvulsive therapy patients compared to healthy controls. Brain Stimulation 2023, 17: 140-147. PMID: 38101469, PMCID: PMC11145948, DOI: 10.1016/j.brs.2023.12.005.Peer-Reviewed Original ResearchDefault mode networkElectroconvulsive therapyHealthy controlsECT patientsResting-state networksTreatment effectivenessSalience networkElectroconvulsive therapy patientsWhole-brain voxel-wise analysisMajor depressive episodeCanonical resting-state networksRight frontoparietal networkVoxel-wise changesHigh treatment effectivenessVoxel-wise analysisNetwork connectivity changesTest-retest variabilityMulticenter studyDepressive episodeDepressed patientsTherapy patientsMagnetic resonance imaging dataDMN connectivityPatientsConnectivity changesDepressive symptoms and anger and aggression in Russian adolescents
Ruchkin V, Stickley A, Koposov R, Sukhodolsky D, Isaksson J. Depressive symptoms and anger and aggression in Russian adolescents. Child And Adolescent Psychiatry And Mental Health 2023, 17: 130. PMID: 37974287, PMCID: PMC10652468, DOI: 10.1186/s13034-023-00677-w.Peer-Reviewed Original ResearchComorbid mental health problemsMental health problemsAnger ruminationComorbid problemsDepressive symptomsTypes of angerAggressive behaviorOvert aggressive behaviorLevel of depressionAggression variablesVerbal aggressionSocial aggressionRussian adolescentsAngerGeneral population sampleDepressive episodeAggressionInconsistent findingsAdolescentsHealth problemsCurrent major depressive episodeSubthreshold depressive symptomsRuminationMajor depressive episodeSignificant depressive episodeEffect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventionsRising Rates of Suicidal Behaviors and Large Unmet Treatment Needs Among US Adults With a Major Depressive Episode, 2009 to 2020
Bommersbach T, Rosenheck R, Rhee T. Rising Rates of Suicidal Behaviors and Large Unmet Treatment Needs Among US Adults With a Major Depressive Episode, 2009 to 2020. Mayo Clinic Proceedings 2023, 98: 969-984. PMID: 37419587, DOI: 10.1016/j.mayocp.2023.02.012.Peer-Reviewed Original ResearchConceptsMajor depressive episodePast-year major depressive episodeMental health service useMultivariable-adjusted analysesHealth service usePast-year suicidal ideationSubstance use disordersSuicidal ideationSuicide attemptsUse disordersOdds ratioService useUnmet treatment needCoronavirus disease 2019 (COVID-19) pandemicMental health servicesMental health treatmentAlcohol use disorderDisease 2019 pandemicRates of SIHispanic patientsUnmet treatmentDepressive episodeUnadjusted proportionTreatment needsUS adultsGroup independent components underpin responses to items from a depression scale.
Stoyanov D, Khorev V, Paunova R, Kandilarova S, Kurkin S, Calhoun V. Group independent components underpin responses to items from a depression scale. Acta Neuropsychiatrica 2023, 36: 9-16. PMID: 37088536, DOI: 10.1017/neu.2023.22.Peer-Reviewed Original ResearchConceptsFunctional magnetic resonance imagingGroup independent component analysisSelf-evaluation scaleFrontal gyrusCingulate cortexDepression ScaleRight superior frontal gyrusFunctional magnetic resonance imaging acquisitionHealthy controlsRight middle cingulate cortexAnterior cingulate cortexMiddle frontal gyrusSuperior frontal gyrusMiddle cingulate cortexIndependent component analysisGroup independent componentStatistical parametric mappingDepressive disorderDepressive episodeBrain circuitsBrain networksNeural network patternsDiagnostic conditionsParametric mappingGyrusSerotonin 4 Receptor Brain Binding in Major Depressive Disorder and Association With Memory Dysfunction
Köhler-Forsberg K, Dam V, Ozenne B, Sankar A, Beliveau V, Landman E, Larsen S, Poulsen A, Ip C, Jørgensen A, Meyer M, Stenbæk D, Eiberg H, Madsen J, Svarer C, Jørgensen M, Frokjaer V, Knudsen G. Serotonin 4 Receptor Brain Binding in Major Depressive Disorder and Association With Memory Dysfunction. JAMA Psychiatry 2023, 80: 296-304. PMID: 36753296, PMCID: PMC9909578, DOI: 10.1001/jamapsychiatry.2022.4539.Peer-Reviewed Original ResearchConceptsMemory dysfunctionUntreated MDDDepressive disorderReceptor bindingHealthy controlsModerate to severe depressive episodePositron emission tomographyMajor depressive disorderSevere depressive episodeVerbal memory performanceNeurobiological signatureDepressive episodeVerbal memoryMemory performanceCognitive domainsDepression trialsMDDDepressive stateBrain bindingCognitive testsCognitive functionGroup differencesAssociated with improved learningSerotonin-4Adult participantsPredictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray
Turkoz I, Nelson J, Wilkinson S, Borentain S, Macaluso M, Trivedi M, Williamson D, Sheehan J, Salvadore G, Singh J, Daly E. Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Research 2023, 323: 115165. PMID: 37019044, DOI: 10.1016/j.psychres.2023.115165.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionEsketamine nasal sprayNasal sprayDay 28Day 8Clinical Global Impression-Severity scoreCGI-S scoresCurrent depressive episodePredictors of responsePlacebo nasal sprayIdentification of predictorsOral antidepressantsBaseline patientAcute trialPooled analysisDepressive episodeRemissionPsychiatric characteristicsPatientsSignificant anxietyYounger ageTreatment assignmentPotential predictorsPhase 3Predictors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply